[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69309044D1 - Behandlung von asthma - Google Patents

Behandlung von asthma

Info

Publication number
DE69309044D1
DE69309044D1 DE69309044T DE69309044T DE69309044D1 DE 69309044 D1 DE69309044 D1 DE 69309044D1 DE 69309044 T DE69309044 T DE 69309044T DE 69309044 T DE69309044 T DE 69309044T DE 69309044 D1 DE69309044 D1 DE 69309044D1
Authority
DE
Germany
Prior art keywords
asthma
treatment
eosinophils
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69309044T
Other languages
English (en)
Other versions
DE69309044T2 (de
DE69309044T3 (de
Inventor
Roy Lobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25234272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69309044(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of DE69309044D1 publication Critical patent/DE69309044D1/de
Publication of DE69309044T2 publication Critical patent/DE69309044T2/de
Application granted granted Critical
Publication of DE69309044T3 publication Critical patent/DE69309044T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69309044T 1992-01-13 1993-01-12 Behandlung von asthma Expired - Lifetime DE69309044T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82176892A 1992-01-13 1992-01-13
US821768 1992-01-13
PCT/US1993/000030 WO1993013798A1 (en) 1992-01-13 1993-01-12 Treatment for asthma

Publications (3)

Publication Number Publication Date
DE69309044D1 true DE69309044D1 (de) 1997-04-24
DE69309044T2 DE69309044T2 (de) 1997-09-25
DE69309044T3 DE69309044T3 (de) 2004-12-23

Family

ID=25234272

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69309044T Expired - Lifetime DE69309044T3 (de) 1992-01-13 1993-01-12 Behandlung von asthma

Country Status (10)

Country Link
EP (1) EP0626861B2 (de)
JP (4) JPH07506091A (de)
AT (1) ATE150319T1 (de)
CA (1) CA2127462C (de)
DE (1) DE69309044T3 (de)
DK (1) DK0626861T4 (de)
ES (1) ES2102009T5 (de)
GR (1) GR3023203T3 (de)
HK (1) HK1007682A1 (de)
WO (1) WO1993013798A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
EP0670735B1 (de) 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralisierung hämatopoietischer stammzellen
DK0678122T3 (da) * 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
EP0682529B2 (de) * 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antikörper zur behandlung von insulinabhängigem diabetes
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) * 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP2065050A1 (de) 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Verfahren zur Behandlung von multiplem Myelom und von Myelom induzierter Knochenresorption unter Anwendung von Integrin-Antagonisten
IL145898A0 (en) 1999-04-22 2002-07-25 Biogen Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1488806B1 (de) 1999-06-01 2015-12-09 Biogen MA Inc. Ein blockierender monoklonaler Antikörper gegen VLA-1 und dessen Verwendung zur Behandlung von vaskulären Krankheiten
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
MXPA03009390A (es) 2001-04-13 2004-01-29 Biogen Inc Anticuerpos para integrina vla-1.
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
EP1477482B1 (de) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Neues phenylalaninderivat
CA2550843C (en) 2003-12-22 2013-04-02 Ajinomoto Co., Inc. Novel phenylalanine derivatives
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
MX2008014793A (es) 2006-05-25 2008-12-02 Biogen Idec Inc Metodos para tratar la apoplejia.
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
KR20110008086A (ko) 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
BR112012026403B1 (pt) 2010-04-16 2022-10-04 Biogen Ma Inc Molécula de anticorpo recombinante ou um fragmento de ligação a ?4 da mesma e seu uso
AU2013221635B2 (en) 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
KR20210027352A (ko) 2018-06-04 2021-03-10 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
IL294921A (en) 2020-01-24 2022-09-01 Pfizer Antibodies against E-selectin, preparations and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) † 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) † 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
DK162890D0 (da) 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
DK0626861T3 (da) 1997-09-22
ES2102009T3 (es) 1997-07-16
ES2102009T5 (es) 2004-12-16
EP0626861B2 (de) 2004-04-28
JP4590152B2 (ja) 2010-12-01
CA2127462C (en) 1999-03-23
HK1007682A1 (en) 1999-04-23
DE69309044T2 (de) 1997-09-25
AU665232B2 (en) 1995-12-21
GR3023203T3 (en) 1997-07-30
DE69309044T3 (de) 2004-12-23
WO1993013798A1 (en) 1993-07-22
ATE150319T1 (de) 1997-04-15
EP0626861A1 (de) 1994-12-07
JP2006316070A (ja) 2006-11-24
JPH07506091A (ja) 1995-07-06
JP2003176239A (ja) 2003-06-24
JP2010285444A (ja) 2010-12-24
CA2127462A1 (en) 1993-07-22
AU3431793A (en) 1993-08-03
DK0626861T4 (da) 2004-08-16
EP0626861B1 (de) 1997-03-19

Similar Documents

Publication Publication Date Title
DE69309044D1 (de) Behandlung von asthma
ATE161730T1 (de) Antikörper zur behandlung von insulinabhängigen diabetes
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
PT723538E (pt) Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
DE69211403D1 (de) Multifunktionelle wasserdispergierbare Verknüpfungsmittel
BG44538A3 (en) Method for preparing salts of 5- metoxy- 2- big bracket [(4- metoxy- 3, 5- dimethyl- 2- pyridinyl)- methyl] sulphonyl- 1h- benzimidazol
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
DE69129800D1 (de) Behandlung von menschlichen retrovirus-infektionen mit 2',3'-dideoxyinosin
IT8622630A0 (it) Anticorpi monoclonali crossreattivi e cross-protettivi contro sierotipi di p. aeruginosa.
HUP9900935A2 (hu) Baktériumellenes és gombaellenes hatású peptid és eljárás az előállítására
GR3026519T3 (en) New method of treating depression
HU9501288D0 (en) Recombinant method and host for manufacture of xylitol
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
FI854383A0 (fi) Foerfarande foer avspaltning av peptider och proteiner av metionyl-bindning.
DE68921229D1 (de) Prozess zur Behandlung von unlöslichem heterogenem Fusionsprotein.
DK0646176T3 (da) Levering og ekspression af et hybridoverfladeprotein på overfladen af grampositive bakterier
DE69330268D1 (de) Hämoregulierende peptide
DK0383599T3 (da) Protein-anticancermiddel
DE59310073D1 (de) Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
EP0235904A3 (de) Behandlung von Allergie mit Thymopentin
DE59006159D1 (de) Verwendung von macrolactonen als antiallergica.
IT8819286A0 (it) Procedimento per il trattamento extracorporeo di liquido ascitico.
KR950701347A (ko) 신규한 향종양성 사이토킨(A novel anti-neoplastic cytokine)
DE68909118D1 (de) Verfahren zur Ausscheidung von 2,6-Dimethylnaphthalin.
DE68914950D1 (de) Aminsalze von 1,4,2-Oxazaphospholidin-2-alkoxy-2-oxid-4-essigsäuren.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
R071 Expiry of right

Ref document number: 626861

Country of ref document: EP